10-Q: Pasithea Therapeutics Q1 2026 Financial Results

Pasithea Therapeutics reports a net loss of $2.9 million for Q1 2026 as it continues clinical development of its lead candidate, PAS-004.

Summary

• Reported a net loss of $2.87 million for the three months ended March 31, 2026, compared to a net loss of $3.56 million in the same period of 2025.
• Operating expenses totaled $4.88 million, driven primarily by research and development costs of $2.94 million.
• Maintained a strong liquidity position with $50.4 million in cash and cash equivalents as of March 31, 2026.
• Completed initial eight cohorts of the FIH Phase 1 Advanced Cancer Study for PAS-004 without reaching the maximum tolerated dose.
• Filed a protocol amendment to continue dose escalation using a tablet formulation of PAS-004.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral report; while the company maintains a healthy cash runway, the lack of revenue and the explicit need for future capital raises keep the risk profile elevated.

Positives

• Strong cash position of $50.4 million provides runway for at least 12 months of operations.
• Successfully reclassified December 2025 Placement Agent Warrants from liability to equity following shareholder approval to increase authorized shares.
• Clinical progress continues with the FIH Phase 1 Advanced Cancer Study and the Phase 1/1b trial for NF1-PN.
• Net loss narrowed by approximately 19.5% compared to the first quarter of 2025.

Negatives

• Continued reliance on external capital, as the company has no product revenue and recurring operating losses.
• Research and development expenses increased by 70.1% year-over-year to $2.94 million.
• Accumulated deficit reached $72.9 million as of March 31, 2026.

Risks

• Significant uncertainty regarding the timing and success of clinical trials for PAS-004.
• Dependence on future equity or debt financing to sustain operations beyond the next 12 months.
• Potential for future dilution of existing shareholders through capital raises.
• Risks associated with regulatory approval processes and potential failure to meet clinical endpoints.
• Impact of inflationary pressures on operating costs and employee compensation.

Future Outlook

The company expects to continue incurring significant operating losses as it advances PAS-004 through clinical trials, with an expected completion of the FIH Phase 1 Advanced Cancer Study in 2028. Management believes current cash is sufficient for at least 12 months but emphasizes the need for future capital raises to support long-term development.

Management Comments

• Management notes that the company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities.
• Management believes that the current available cash and cash equivalents will be sufficient to meet working capital needs for at least the next twelve months.

Industry Context

StockSavvy.ai notes that Pasithea is operating in a capital-intensive clinical-stage biotech environment where cash preservation and clinical milestone achievement are the primary drivers of valuation. The shift toward tablet formulations and dose escalation in oncology trials is a standard industry practice to optimize therapeutic windows.

Comparison to Industry Standards

• The company's reliance on ATM offerings and warrant-heavy financing is common for small-cap clinical-stage biotech firms.
• The focus on RASopathies and MAPK pathway-driven tumors aligns with current industry trends in precision oncology, similar to companies like Mirati Therapeutics or Blueprint Medicines.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Consulting agreement with Prof. Lawrence Steinman, with quarterly compensation reduced to $1.00 effective October 1, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Clinical trial participants are impacted by the ongoing dose escalation and formulation changes.

Next Steps

• Continue dose escalation in the FIH Phase 1 Advanced Cancer Study using the tablet formulation.
• Conduct a pilot food effect assessment for PAS-004.
• Advance the Phase 1/1b trial for NF1-PN in adult patients.
• Plan for future pediatric NF1-PN clinical trials.

Key Dates

Recommendation

The company has a stable cash position for the next year, but the lack of near-term revenue and the necessity for future dilution make it a hold until significant clinical efficacy data is released.

Keywords

Pasithea Therapeutics, KTTA, PAS-004, Biotechnology, Clinical Trials, RASopathies, MEK inhibitor, SEC Filing